Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Clinical management of cutaneous adverse events in patients on

HER-2 directed therapy in advanced breast cancer

Effects of lapatinib monotherapy: results of a randomised phase II

EGFR Inhibitors and Cutaneous Complications: A Practical Approach

Page 1597 – Cancer Therapy Advisor

OS and PFS stratified by maximum grade of rash, hand foot syndrome

PDF) Lapatinib and lapatinib plus trastuzumab therapy versus

Page 1529 – Cancer Therapy Advisor

Evolution of Case 2-cutaneous metastasis: (A) before TDM1

Immune Checkpoint Inhibitors & Immune-Related Adverse Events - The

PDF] Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO

Trastuzumab or lapatinib with standard chemotherapy for HER2

Lapatinib in Breast Cancer

Cancers, Free Full-Text

/cms/10.1021/acs.chemrestox.5b00524/as